Articles tagged "Renal function"

2019 American Transplant Congress
Renal Recovery and Prognostic Factors in Children Following Liver Transplantation
R. Büscher, N. Gantenberg, A. Büscher, E. Lainka, P. Hoyer
Department of Pediatrics II, University Hospital Essen, Essen, Germany
*Purpose: Progression to chronic renal disease (CKD) is highly prevalent in adults following liver transplantation (LT) with a profound impact on patient survival, assuming that…
2019 American Transplant Congress
Belatacept Use in High Kidney Donor Profile Index Kidney Transplant Recipients
D. Britt¹, A. Gharabagi¹, K. Botkin¹, T. Horwedel², C. Carthon¹, J. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: To determine whether the use of belatacept is associated with renal function preservation in kidney transplant recipients from donors with a kidney donor profile…
2019 American Transplant Congress
Prediction of Renal Allograft Chronic Rejection Using a Model Based on Contrast Enhanced Ultrasonography
C. Yang¹, T. Zhu¹, W. He²
¹Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China, ²Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China
*Purpose: To evaluated the application of contrast enhanced ultrasonography (CEUS) in diagnosis of renal allograft chronic rejection (CR).*Methods: Sixty-six renal transplantation recipients were enrolled in…
2019 American Transplant Congress
Estimated Glomerular Filtration Rate at Donor Screening to Predict Measured Glomerular Filtration Rate after Living Kidney Donation
J. van der Weijden, M. van Londen, M. Y. Said, S. J. Bakker, S. P. Berger, G. Navis, M. H. de Borst
Nephrology, University Medical Center Groningen, Groningen, Netherlands
*Purpose: Accurate post-donation renal function prediction is important to minimize the risk of future severe renal function impairment in living kidney donors. Recent studies focused…
2019 American Transplant Congress
Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM
C. Legendre¹, S. Berger¹, F. Oppenheimer¹, A. Wiseman¹, S. Steinberg¹, O. Viklicky¹, G. Russ¹, R. Danguilan¹, N. Basic-Jukic¹, E. Mor¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², C. Sommerer¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…
2019 American Transplant Congress
Simultaneous Recipient Iliac Endarterectomy and Renal Transplantation: A Propensity Score Matched Study
O. Okoye, M. Spaggiari, J. Almario, V. Qiao, K. Tulla, P. Di Cocco, E. Benedetti, I. Tzvetanov
General surgery, University of Illinois at Chicago, Chicago, IL
*Purpose: Severe iliac atherosclerotic disease can jeopardize the success of, and listing of patients for renal transplantation. Not only does it provide a technical challenge…
2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
L. Coromina¹, S. Shah², B. Xervos³, M. Zimmerman⁴, K. Sasaki¹, T. Diago¹, K. Hashimoto¹, F. Aucejo¹, m. Fujiki¹, H. Block-Beach¹, A. Patterson², C. Miller¹, C. Quintini¹, B. Eghtesad¹
¹The Cleveland Clinic, Cleveland, OH, ²University of Cincinnati, Cincinnati, OH, ³The Cleveland Clinic, Weston, FL, ⁴Medical College of Wisconsin, Milwaukee, WI
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…
2019 American Transplant Congress
Urinary Biomarkers of Kidney Injury in Liver Transplant Recipients with Calcineurin Inhibitors Based Immunosuppression
D. Maluf¹, V. Bontha¹, A. Bajwa², A. Abdelaal¹, C. Koo¹, J. D. Eason², V. Mas²
¹UTHSC, Memphis, TN, ²Transplant Institute, Memphis, TN
*Purpose: Renal dysfunction post solid organ transplantation is common and associated with several risk factors. Messenger RNA encoding for genes expressed along the nephron and…
2019 American Transplant Congress
A Prospective, Randomized, Multicenter Trial of Bela-Based CNI Free and Steroid Withdrawal Immunosuppression: Best Trial Two Year Characterization of Rejection and Renal Function
A. Wiseman¹, A. R. Shields², R. R. Alloway², D. Kaufman³, J. P. Leone⁴, A. J. Matas⁵, P. West-Thielke⁶, J. Lipscomb², E. King², E. S. Woodle for the BEST Study Group²
¹University of Colorado School of Medicine, Denver, CO, ²University of Cincinnati, Cincinnati, OH, ³University of Wisconsin, Madison, WI, ⁴Tampa General, Tampa, FL, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Illinois, Chicago, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) was designed to compare two BELA-based early steroid withdrawal (ESW) regimens with a TAC-based ESW regimen…
2019 American Transplant Congress
Recipients with Model for End-Stage Liver Disease Sodium Score Driven by Renal Dysfunction Have Increased Post-Transplant Mortality
T. Bittermann, D. Goldberg
Gastroenterology, University of Pennsylvania, Philadelphia, PA
*Purpose: Since the adoption of the Model for End-stage Liver Disease (MELD) score as a primary means of waitlist prioritization for liver transplantation (LT), an…